Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Elevian has launched with $5.5 million in seed funding to pursue regenerative medicines for aging and age-related diseases. Based on work done in the labs of its scientific cofounder, Harvard University professor Amy Wagers, the biotech is developing therapeutics that increase the activity of growth-differentiating factor 11, a circulating factor that when given to mice elicits the regenerative benefits of young blood. Enhancing GDF11 levels could treat diseases such as Alzheimer’s, type 2 diabetes, and age-related muscle disorders, Elevian says.
This article has been sent to the following recipient: